We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Homozygosity for rs17775810 Minor Allele Associated With Reduced Mortality of COVID-19 in the UK Biobank Cohort.
- Authors
LEHRER, STEVEN; RHEINSTEIN, PETER H.
- Abstract
Background/Aim: Adult outpatients with symptomatic COVID-19 treated with fluvoxamine, compared with placebo, had a lower likelihood of clinical deterioration over 15 days. Fluvoxamine strongly binds to the sigma-1 receptor (S1R) that regulates inflammation by inhibiting the production of cytokines, believed to be responsible for severe COVID-19. We evaluated the S1R locus on chr 9p13.3 in subjects tested positive for SARS-CoV-2. We focused on SNP rs17775810 that has been previously identified by examining loss-of-function mutations in the S1R gene associated with distal hereditary motor neuropathy. Patients and Methods: We utilized UK Biobank (UKB) data. Data processing was performed on Minerva, a Linux mainframe with Centos 7.6, at the Icahn School of Medicine at Mount Sinai. Results: The effect of rs17775810 genotype on survival was significant (p=0.036, 2 tailed Fisher exact test). The minor allele homozygotes (TT) had the lowest death rate (0%), whereas the non-TT genotypes (i.e. CT and CC) had the highest death rate (16.2%). Conclusion: The rs17775810 analysis corroborates the favorable effect of fluvoxamine on COVID19 survival.
- Subjects
HOMOZYGOSITY; MORTALITY; COVID-19; FLUVOXAMINE; BIOBANKS
- Publication
In Vivo, 2021, Vol 35, Issue 2, p965
- ISSN
0258-851X
- Publication type
Article
- DOI
10.21873/invivo.12338